Rabies post-exposure prophylaxis

This entity refers to the clinical and public-health response given after possible rabies exposure, commonly termed rabies post-exposure prophylaxis (PEP) ^[2]. It is tied to rabies, a zoonotic and fatal progressive neurological infection caused by rabies virus in the genus Lyssavirus and family Rhabdoviridae ^[1]. The source material emphasizes that modern cell-culture vaccines have reduced the volume and number of doses required for PEP, and that one-week intradermal regimens have been evaluated for recommendation ^[2].

The sources do not describe a distinct symptom complex for post-exposure prophylaxis itself, because PEP is an intervention rather than an illness. Its clinical relevance is framed by the underlying rabies risk, which is described as a fatal progressive neurological infection with a highly variable incubation period, from 2 weeks to 6 years, averaging 2 to 3 months ^[1]. Rabies is reported to produce severe neurologic signs and a fatal outcome, although neuropathological lesions are described as relatively mild ^[1]. The available snippets do not provide source-backed detail on adverse-event patterns, timing windows, or specific clinical follow-up criteria beyond noting that patient follow-up was one of the criteria considered in regimen evaluation ^[2].

Rabies is described as prevalent worldwide and endemic in many countries, with exceptions noted in islands like Australia and Antarctica ^[1]. The burden is substantial in the cited review, which states that more than 60,000 people die each year from rabies and that approximately 15 million people receive rabies PEP annually ^[1]. Mass bat exposure events have been reported in Rhode Island and in published case series spanning settings such as camping sites, a domestic flight, a neonatal intensive care unit, and dormitories ^[3]. The same review found that potential exposure events ranged from 5 to 1,429 people, underscoring that surveillance may encounter both individual and mass-exposure contexts ^[3].

The cited sources identify bites of rabid animals and saliva of infected hosts as the main routes responsible for rabies transmission ^[1]. Wildlife reservoirs named in the review include raccoons, skunks, bats, and foxes ^[1]. The mass bat exposure report indicates that people may be considered exposed in shared settings when potential contact occurs during sleep, although the snippets do not define a complete exposure algorithm ^[3].

The provided sources do not define formal risk groups for this surveillance concept in a comprehensive way. They do indicate that people living at risk of exposure on a daily basis may face affordability barriers to PEP ^[2]. Mass bat exposure investigations included groups of individuals who were asleep during potential exposure, and published events occurred in settings such as camping sites, a domestic flight, a neonatal intensive care unit, and dormitories ^[3]. Beyond these source-backed observations, specific high-risk groups are not yet available from the supplied material.

Prevention in this surveillance concept centers on prompt rabies PEP after exposure, with modern cell-culture vaccines described as highly potent and well tolerated ^[2]. The literature cited in the payload discusses evaluation of a new one-week intradermal regimen, with criteria including cost-effectiveness, number of doses, seroconversion, efficacy, safety, and patient follow-up ^[2]. The sources also note that affordability and indirect costs such as travel, loss of work time, and accommodation can affect access to and completion of PEP ^[2]. In mass bat exposure situations, public-health authorities may recommend PEP for selected exposed persons, but the review notes substantial variability across events and calls for clearer federal guidance ^[3].

In surveillance, this code should be read as documentation of rabies exposure management rather than confirmed rabies disease [disease metadata]. Useful monitoring signals from the sources include the exposure setting, whether the event involved bats or other rabid-animal contact, whether the event was mass or individual, and whether PEP was provided after assessment ^[3][1]. The literature also highlights variability in PEP recommendations across mass exposure events, suggesting that surveillance interpretation should distinguish exposure investigation, recommendation, and administration where possible ^[3]. Source-backed detail on standardized timing, completeness metrics, or formal follow-up outcomes is not yet available in the provided material ^[2][3].

1. 1 Singh R et al. Rabies - epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review. Vet Q. 2017 Dec. PMID: 28643547. doi: 10.1080/01652176.2017.1343516. PubMed: https://pubmed.ncbi.nlm.nih.gov/28643547/
2. 2 Tarantola A et al. Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine. 2019 Oct 3. PMID: 30471958. doi: 10.1016/j.vaccine.2018.10.103. PubMed: https://pubmed.ncbi.nlm.nih.gov/30471958/
3. 3 Rabies Post-Exposure Prophylaxis. New England Journal of Medicine. 1987. doi: 10.1056/nejm198705143162009. DOI: https://doi.org/10.1056/nejm198705143162009
4. 4 Choe YJ et al. Post-exposure rabies prophylaxis for mass bat exposures: Case series and systematic review. Zoonoses Public Health. 2020 Jun. PMID: 32347667. doi: 10.1111/zph.12706. PubMed: https://pubmed.ncbi.nlm.nih.gov/32347667/
5. 5 Rabies: Post-exposure prophylaxis in man. Annales de l'Institut Pasteur / Virologie. 1985. doi: 10.1016/s0769-2617(85)80134-9. DOI: https://doi.org/10.1016/s0769-2617(85)80134-9
6. 6 Rabies Pre-exposure Immunization Effects on Rabies Post-exposure Prophylaxis. Kansenshogaku Zasshi. 2010. doi: 10.11150/kansenshogakuzasshi.84.474. DOI: https://doi.org/10.11150/kansenshogakuzasshi.84.474

ICD-10

Z20.3

ICD-11

Total cases

9.7M

Peak month

2025-01

Coverage

1 reporting countries · 2006-01-01 → 2026-05-01